Contact Us
Drug Search Results
More Filters [+]

GSK-2292767

Alternative Names: gsk-2292767, gsk2292767, gsk 2292767
Latest Update: 2018-07-24
Latest Update Note: Clinical Trial Update

Product Description

a novel low-solubility inhaled phosphoinositide 3-kinase delta (PI3K_) inhibitor developed as an alternative to 2-(6-(1H-indol-4-yl)-1H-indazol-4-yl)-5-((4-isopropylpiperazin-1-yl)methyl)oxazole (nemiralisib), which is a highly soluble inhaled inhibitor of PI3K_Êwith a lung profile consistent with once-daily dosing.Ê (Sourced from: https://pubmed.ncbi.nlm.nih.gov/30940692/)

Mechanisms of Action: PI3K Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Inhalant

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2292767

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Asthma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
NCT03045887

P1

Completed

Asthma

2017-08-11

52%

Recent News Events

Date

Type

Title

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions